Five patients with confirmed congenital amegakaryocytic thrombocytopenia (CAT) underwent stem cell transplantation (SCT) from HLA-matched related donors at King Faisal Specialist Hospital and Research Center (KFSHRC). The median age at SCT was 3.2 years (range, 0.4-5 years). Conditioning regimen consisted of busulfan (BU) 4 mg/kg p.o. for 4 days (total dose of 16 mg/kg), and cyclophosphamide (CY) 50 mg/kg once daily i.v. for 4 days (total dose of 200 mg/kg). Antithymocyte globulin (ATG) was given i.v. at a dose of 30 mg/ kg for 4 days pre-SCT (total of 120 mg/kg); graft-versushost disease (GVHD) prophylaxis was with cyclosporine and methotrexate. Four patients engrafted and are alive and transfusion independent with a median follow up time of 30 months (range, 16-45 months). One patient failed to engraft and underwent a second SCT 4 months later but died of respiratory failure. We conclude that the use of allogeneic SCT may be curative for such patients.
tic; stem cell transplantation Congenital amegakaryocytic thrombocytopenia (CAT) is a rare syndrome characterized by decreased or absent megakaryocytes on bone marrow examination. Two types of CAT have been described. 1 One type is thrombocytopenia with absent radii (TAR), which is usually diagnosed at birth because of the characteristic physical appearance (bilaterally absent radii with presence of the thumbs) with thrombocytopenia. In most patients with TAR, the platelet count normalizes slowly after the first year; therefore, the management is usually supportive with platelet transfusions for significant bleeding, and allogeneic stem cell transplantation (SCT) is not recommended for such cases except for life-threatening conditions such as an intracranial hemorrhage. 2 The other type is CAT without associated radial anomalies; these patients are often platelet transfusion dependent and succumb in their first year of life to severe bleeding, and the only known curative therapeutic modality for such patients is allogeneic SCT. [3] [4] [5] [6] In this article, we report our experience in five patients with CAT who were treated with allogeneic SCT.
Patients and methods

Patients
From January 1999 through September 2002, five (three male and two female) patients with CAT underwent SCT from matched related donors at KFSHRC. Diagnosis of CAT was confirmed by documenting low platelet counts and absence of megakaryocytes on bone marrow examination. Antiplatelet antibodies were negative. Chromosomal breakage studies to rule out Fanconi's anemia were negative and cytogenetic analysis was normal in all cases. None of the patients had any physical anomalies. Thrombopoietin levels were not measured on any of the patients. The median age of presentation was 2 months (range, 1 month-2 years). Four patients presented to medical attention with epistaxis and skin bruises and one patient presented with hematuria. The median platelet count at diagnosis was 10 Â 10 9 /l (range: 3-15 Â 10 9 /l). All patients had been platelet transfusion dependent since diagnosis. The median age at SCT was 3.2 years (range, 0.4-5 years) ( Table 1) .
Donors
Three donors were HLA-identical siblings and two were HLA-identical parents. The source of stem cells in all cases was bone marrow. The harvested bone marrows were not manipulated and median CD34-positive cell count was 5 Â 10 6 /kg of recipient body weight (range: 4-13 Â 10 6 /kg).
Preparative regimen
The conditioning regimen consisted of busulfan (BU) 4 mg/ kg p.o. in divided doses daily on days -10, À9, À8, and À7 (total dose of 16 mg/kg), cyclophosphamide (CY) 50 mg/kg once daily i.v. on days -5, À4, À3, and À2 (total dose of 200 mg/kg). Equine antithymocyte globulin (ATG) was given i.v. at a dose of 30 mg/kg on days -5, À4, À3, and À2 (total of four doses).
Graft-versus-host disease (GVHD) prophylaxis
All patients received cyclosporin A (CSA) at 3 mg/kg i.v. q 12 h (CSA administration was changed to p.o. when patient was able to swallow) and methotrexate at 10 mg/m 2 on days 1, 3, and 6 post SCT.
Supportive care
All patients were treated in HEPA-filtered rooms and were isolated until their absolute neutrophil count (ANC) was greater than 0.5 Â 10 9 /l for 3 consecutive days. IVIG was given every 2 weeks at a dose of 0.5 g/kg from day À4 until day þ 90. All patients received acyclovir 45 mg/kg/day from day À3 through day þ 28. All blood products were leukocyte-filtered and irradiated.
Results
Engraftment
Engraftment was defined as an increase in the ANC X0.5 Â 10 9 /l for 3 consecutive days; four patients engrafted at a median of 14 days (range 12-22 days). The days to a self-sustaining platelet count of X20 Â 10 9 /l was 20 days (range 15-170 days). One patient failed to engraft. All patients underwent bone marrow aspiration at day 28 to confirm engraftment or lack thereof. Four patients were supported with G-CSF. Chimerism analysis (VNTR or FISH on peripheral lymphocytes) was performed on three of the surviving patients, and all three demonstrated complete donor chimerism.
GVHD
Acute GVHD grade X2 was observed in three patients (one of the skin, one of the skin and gut, and one of the gut only); it was self-limited in the first patient, resolved after steroid treatment in the second, and the third patient continues to have chronic GVHD of the skin but her symptoms are under control.
Toxicity
Mild VOD was observed in one patient, and it responded to conservative measures. Four patients developed transient hypertension. One patient had delayed platelet engraftment and thus continued to require platelet transfusions up to day þ 170. On day 113 post SCT, he suffered a large intracranial hemorrhage that resulted in severe neurological impairment subsequently. One patient failed to engraft and underwent a second allogeneic SCT from the same donor 4 months from the first transplant after conditioning with CY 60 mg/kg i.v. for 2 days, and fractionated total body irradiation (TBI) at a dose of 1200 cGy. Again, she failed to engraft and succumbed to respiratory distress syndrome presumed to be secondary to pulmonary fungal infection on day 38 post SCT.
Follow up
Four patients are alive with sustained normal platelet counts at a median follow-up time of 30 months (range 16-45 months); one of the patients sustained severe brain injury secondary to intracranial hemorrhage post SCT.
Discussion
CAT is a rare and often fatal disorder presenting with isolated thrombocytopenia in infancy and progressing to pancytopenia in later childhood indicating a general defect in hematopoiesis. 1 While the exact underlying defect of this disorder is not well understood, the problem seems to be due to an intrinsic stem cell defect rather than an abnormality of the bone marrow microenvironment or an inhibitory factor in the patients' plasma. 7 High levels of thrombopoietin (TPO) have been found in the sera of affected patients; 8, 9 TPO is the main regulator of megakaryopoiesis. 10 More recently, a lack of TPO reactivity of platelets and hematopoietic progenitors from patients with CAT has been described. This lack of reactivity was shown to be due to point mutations in the c-mpl gene. 7, 10, 11 Several therapeutic modalities have been tried in the treatment of CAT. Steroid, cyclosporin, and cytokines such as IL 3, Had a second SCT, deceased 5.5
IL-11, GCSF produced only transient responses, 12, 13 and thus allogeneic SCT remains the only curative treatment modality. However, because of the rareness of this disorder, there are only few reports in the literature about the relevance of SCT in the management of CAT. In this series, all patients were heavily transfused prior to SCT; therefore, ATG was included in the preparative regimen to minimize the risk of rejection. Four patients engrafted and now enjoy normal platelet counts. Two developed acute GVHD grade X2 and one developed chronic GVHD but is in remission now. One patient failed the first SCT, and underwent a second transplantation from the same donor. She died of pulmonary infection before engraftment. Lackner et al 3 reported their experience in eight patients with CAT; five patients underwent SCT from related donors, two from unrelated donors (MUD), and one from a haploidentical mother (T-cell depleted peripheral stem cells). Preparative regimen was BU/CY/ATG in six patients, BU/CY only in one patient and BU/CY and thiotepa in another patient. Both patients with matched unrelated donor transplants died, the other six patients are well with normal platelet counts 3-27 months post SCT.
Others have also pursued alternative donor SCT for those patients without suitable related donors; MacMillan et al 4 transplanted two children with CAT from matched unrelated donors after a preparative regimen of CY and TBI, both failed initial engraftment and required further donor stem cell infusions and are now well with sustained engraftment, grade I GVHD of the skin was reported in the two patients. Similarly, Kudo et al 5 reported two patients with CAT who received matched unrelated SCT after conditioning with CY/TBI and ATG, no GVHD was reported, both engrafted but one died of recurrent pneumonia.
In conclusion, we recommend that allogeneic SCT be considered for patients with CAT; the procedure should be performed early in life before the development of platelet antibodies from repeated platelet transfusions and before the progression to pancytopenia. Those who lack a suitable related match may be considered for unrelated SCT.
